Melinda Magyari
Overview
Explore the profile of Melinda Magyari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
172
Citations
1750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Framke E, Magyari M
Ther Adv Neurol Disord
. 2025 Feb;
18:17562864251313918.
PMID: 39958832
Background: In multiple sclerosis (MS), the educational gradient in diagnostic and disease-modifying treatment (DMT) delays is sparsely examined, and the results are mixed. Objectives: Among patients with relapsing-remitting MS (RRMS),...
2.
Heerfordt I, Framke E, Windfeld-Mathiasen J, Magyari M, Horwitz H
Mult Scler Relat Disord
. 2025 Feb;
94:106299.
PMID: 39919501
Background: Low uric acid levels have been observed in patients with multiple sclerosis (MS). As allopurinol is commonly used to lower uric acid in gout patients, this study examined allopurinol...
3.
Elberling F, Mahler M, Pontieri L, Sellebjerg F, Magyari M
Eur J Neurol
. 2025 Feb;
32(2):e70042.
PMID: 39895213
Background And Objective: High-efficacy (HE) disease-modifying therapies (DMT) are increasingly used to treat multiple sclerosis (MS). Concerns arise when considering the decreasing efficacy and increasing risk of adverse events in...
4.
Hellwig K, Magyari M, MacDonald T, Cesta C, Wergeland S, Leinonen M, et al.
Ther Adv Neurol Disord
. 2025 Jan;
18:17562864241310996.
PMID: 39872126
Background: Cladribine tablets are contraindicated during pregnancy; therefore, safety data on pregnancies exposed to this treatment are limited. CLEAR collects and describes pregnancy outcomes in this understudied population. Objectives: To...
5.
Pontieri L, Greene N, Wandall-Holm M, Geertsen S, Asgari N, Jensen H, et al.
Brain Commun
. 2024 Dec;
6(6):fcae422.
PMID: 39713244
Currently, there are limited therapeutic options for patients with non-active secondary progressive multiple sclerosis. Therefore, real-world studies have investigated differences between patients with relapsing-remitting multiple sclerosis, non-active secondary progressive multiple...
6.
Androdias G, Lunemann J, Maillart E, Amato M, Audoin B, Bruijstens A, et al.
Brain
. 2024 Dec;
PMID: 39707906
The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs...
7.
Beczek A, Landt E, Storr L, Beck M, Pontieri L, Magyari M, et al.
Mult Scler J Exp Transl Clin
. 2024 Dec;
10(4):20552173241307619.
PMID: 39703811
Background: In Denmark, specialized multiple sclerosis (MS) clinics offer free-of-charge treatment to people with MS. However, not all people with MS attend regular clinical follow-up. Objective: To identify people with...
8.
Merki-Feld G, Bove R, Haddad L, Hellwig K, Hillert J, Houtchens M, et al.
Eur J Contracept Reprod Health Care
. 2024 Dec;
:1-15.
PMID: 39676715
Purpose: Multiple sclerosis (MS) is often diagnosed in people of reproductive age. However, family planning counselling is not always integrated within MS care. Decisions on family planning can be further...
9.
Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, et al.
J Neurol Neurosurg Psychiatry
. 2024 Dec;
PMID: 39643429
Background: Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains...
10.
Framke E, Sellebjerg F, Kant M, Stilund M, Jensen H, Illes Z, et al.
Mult Scler
. 2024 Dec;
31(1):36-43.
PMID: 39632560
Background: Teriflunomide has been associated with an increased risk of hypertension. Real-world studies including adequate control groups are lacking. We hypothesized that patients with multiple sclerosis (MS) treated with teriflunomide...